June 3, 2019

Edward Kaye
Chief Executive Officer
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, MA 01730

       Re: Stoke Therapeutics, Inc.
           Registration Statement on Form S-1
           Filed May 23, 2019
           File No. 333-231700

Dear Dr. Kaye:

       We have reviewed your registration statement and have the following
comments. In
some of our comments, we may ask you to provide us with information so we may
better
understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our May 14, 2019
letter.

Registration Statement on Form S-1

Description of capital stock
Anti-takeover provisions
Restated certificate of incorporation and restated bylaw provisions, page 151

1.     We note your response to comment 8 in our letter dated April 17, 2019
that it is the
       registrant's position that the reference "to the fullest extent
permitted by law" in your
       certificate of incorporation is sufficient to indicate that your
exclusive forum provision
       will not apply to actions brought under the Exchange Act. However, this
may not be clear
       to investors. If you do not intend to state in your certificate of
incorporation that the
       provision does not apply to actions arising under the Exchange Act,
please tell us how you
       will inform investors in future filings that the provision does not
apply to any actions
 Edward Kaye
Stoke Therapeutics, Inc.
June 3, 2019
Page 2
         arising under the Exchange Act, as you do on page 153. In addition,
please expand your
         risk factor on page 57 to state that your exclusive forum provision
applies to claims under
         the Securities Act and to address any uncertainty as to whether a
court would enforce an
         exclusive forum provision with respect to claims under the Securities
Act.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Rolf Sundwall at 202-551-3105 or Jim Rosenberg at
202-551-3679 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Justin Dobbie at 202-551-3469 with
any other
questions.



FirstName LastNameEdward Kaye                                 Sincerely,
Comapany NameStoke Therapeutics, Inc.
                                                              Division of
Corporation Finance
June 3, 2019 Page 2                                           Office of
Healthcare & Insurance
FirstName LastName